Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 911 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: B complex Clear all
Completed Not applicable Interventional Accepts healthy volunteers

RCT of an Oral Acne Supplement for Adult Women

NCT06097871
View directory record Official record
Conditions
Acne
Interventions
Skin Nutraceutical Supplement, Placebo pill
Dietary Supplement · Other
Lead sponsor
Nutraceutical Wellness Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 19, 2026, 5:23 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Active, not recruiting Phase 2 Interventional

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

NCT03323463
View directory record Official record
Conditions
HPV-Associated Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Neck
Interventions
F-FMISO PET/CT Scan, 30 Gy over 3 weeks, Cisplatin, Carboplatin, 5Fluorouracil, Proton Therapy
Diagnostic Test · Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

NCT03336216
View directory record Official record
Conditions
Advanced Pancreatic Cancer
Interventions
Cabiralizumab, Nab-paclitaxel, Onivyde, Nivolumab, Fluorouracil, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan Hydrochloride
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 19, 2026, 5:23 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

NCT04216316
View directory record Official record
Conditions
Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Berzosertib, Biospecimen Collection, Carboplatin, Computed Tomography, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
34
States / cities
Los Angeles, California • Newport Beach, California • Aventura, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

NCT02041533
View directory record Official record
Conditions
Stage IV or Recurrent Non-Small Cell Lung Cancer
Interventions
Nivolumab, Gemcitabine, Cisplatin, Carboplatin, Paclitaxel, Pemetrexed
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
36
States / cities
Mobile, Alabama • Gilbert, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

NCT03798626
View directory record Official record
Conditions
Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
Interventions
Gevokizumab, Bevacizumab, Modified FOLFOX6, FOLFIRI, Ramucirumab, Paclitaxel, Cabozantinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Los Angeles, California • St Louis, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Active, not recruiting Phase 2 Interventional

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

NCT04443348
View directory record Official record
Conditions
Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
Interventions
Radiation Therapy Boost, Pembrolizumab, Paclitaxel, Carboplatin, Cyclophosphamide, Doxorubicin, Capecitabine
Radiation · Drug
Lead sponsor
Laura M. Spring, MD
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

NCT00985426
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
HEPLISAV-B, Engerix-B, Placebo
Biological · Other
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 19, 2026, 5:23 AM EDT
Suspended Phase 1 Interventional

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

NCT01604863
View directory record Official record
Conditions
Cancer
Interventions
HGS1036 + Paclitaxel + Carboplatin, HGS1036 + Cisplatin + Etoposide, HGS1036 + Docetaxel
Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Scottsdale, Arizona • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 19, 2026, 5:23 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT04974398
View directory record Official record
Conditions
Nasopharyngeal Carcinoma
Interventions
Penpulimab, placebo
Drug
Lead sponsor
Akeso
Industry
Eligibility
12 Years to 75 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Duarte, California • Atlanta, Georgia • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women

NCT00710593
View directory record Official record
Conditions
HIV Infection
Interventions
HPV vaccine for strains -6, -11, -16, and -18
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 23 Years · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 5:23 AM EDT
Recruiting Phase 2 Interventional

Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients

NCT04948619
View directory record Official record
Conditions
Pediatric Cancer
Interventions
Vaccine
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years to 21 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

NCT07129993
View directory record Official record
Conditions
Urothelial Cancer, Bladder Cancer
Interventions
Dato-DXd, Carboplatin, Cisplatin, Gemcitabine
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
38
States / cities
Fullerton, California • Glendale, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

NCT02096263
View directory record Official record
Conditions
Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions
Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 19, 2026, 5:23 AM EDT
Terminated Phase 1 Interventional Results available

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

NCT02561832
View directory record Official record
Conditions
Breast Cancer
Interventions
Olaparib, Carboplatin, Anthracycline, Cyclophosphamide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
New York, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 19, 2026, 5:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

NCT02957968
View directory record Official record
Conditions
Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive Tumor, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Triple-negative Breast Carcinoma
Interventions
Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Decitabine, Pembrolizumab
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Edgewood, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

NCT00006379
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions
anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide, fludarabine phosphate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Oct 19, 2026, 5:23 AM EDT
Not listed Phase 2 Interventional

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

NCT01372579
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Interventions
eribulin mesylate, carboplatin, biopsy
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Oct 19, 2026, 5:23 AM EDT
Recruiting Phase 3 Interventional

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

NCT07228832
View directory record Official record
Conditions
Metastatic Colorectal Cancer (CRC)
Interventions
Drug: Ivonescimab Injection, Drug: Bevacizumab Injection
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
112
States / cities
Mobile, Alabama • Tuscaloosa, Alabama • Goodyear, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

NCT01311674
View directory record Official record
Conditions
Healthy Volunteers
Interventions
hepatitis B vaccine
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
20 Years to 55 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Altamonte Springs, Florida • Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 19, 2026, 5:23 AM EDT
Recruiting Phase 2 Interventional

NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients

NCT06845319
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Carboplatin, Paclitaxel, Pembrolizumab
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 19, 2026, 5:23 AM EDT
Completed No phase listed Observational

Susceptibility to Chronic Post-Traumatic Extremity Pain

NCT00672711
View directory record Official record
Conditions
Chronic Pain
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Royal Oak, Michigan • Troy, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 19, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

NCT02117934
View directory record Official record
Conditions
Healthy
Interventions
HEPLISAV, Engerix-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
8,374 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 19, 2026, 5:23 AM EDT